News

Hosted on MSN3mon
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
JNJ's Nipocalimab Development Plans Besides gMG and SjD, J&J is also developing nipocalimab in separate mid to late-stage clinical studies for treating autoantibody-driven rare diseases. The ...
Yahoo Finance9mon
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
Johnson & Johnson JNJ submitted abiologics license application (BLA) to the FDA seeking approval for nipocalimab, its investigational neonatal Fc receptor (FcRn) blocker, in generalized myasthenia ...
Stockhouse3mon
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's ...
SPRING HOUSE, Pa., March 18, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track ...
Forbes5mon
What To Expect From JNJ Stock In 2025?
Nipocalimab is expected to be a blockbuster ... This drug may advance to late stage clinical trials. Overall, JNJ stock looks like it will have a mix of positives and negatives to deal with ...
Stockhouse7mon
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction by over 77% following ...
Seeking Alpha7mon
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren ...
making this the second time Johnson & Johnson's (JNJ) nipocalimab has received this designation "Today's announcement marks an important step forward in the continued research and development of ...
Yahoo Finance3mon
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
Johnson & Johnson JNJ announced that the FDA has granted a Fast Track designation (“FTD’) to its investigational drug, nipocalimab, for treating adult patients with moderate-to-severe Sjögren’s ...